UNIVEST FINANCIAL Corp Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

UNIVEST FINANCIAL Corp lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 14,202 shares of the biopharmaceutical company’s stock after selling 1,514 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Regeneron Pharmaceuticals were worth $10,116,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Great Valley Advisor Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 5.0% during the 3rd quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock valued at $465,000 after acquiring an additional 21 shares during the last quarter. Cerity Partners LLC increased its position in Regeneron Pharmaceuticals by 18.5% during the third quarter. Cerity Partners LLC now owns 15,548 shares of the biopharmaceutical company’s stock worth $16,344,000 after purchasing an additional 2,423 shares during the last quarter. Kingsview Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 2.6% during the third quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock worth $904,000 after purchasing an additional 22 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 127.3% in the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 28 shares during the last quarter. Finally, Independent Advisor Alliance purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $231,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $634.14 on Wednesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $687.18 and a 200-day moving average of $806.20. The stock has a market cap of $69.33 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $633.10 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $11.86 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.